Literature DB >> 26623047

Predictors and outcome of complete removal of colorectal cancer with synchronous lung metastases.

Hiroaki Nozawa1, Junichiro Tanaka1, Takeshi Nishikawa1, Toshiaki Tanaka1, Tomomichi Kiyomatsu1, Kazushige Kawai1, Keisuke Hata1, Shinsuke Kazama1, Hironori Yamaguchi1, Soichiro Ishihara1, Eiji Sunami1, Joji Kitayama1, Jun Nakajima2, Norihiro Kokudo3, Toshiaki Watanabe1.   

Abstract

The prognosis-improving effect of radical surgery has been demonstrated in patients with colorectal cancer (CRC) with liver metastases. However, few studies have examined the effectiveness of treatments for CRC with metastases in organs other than the liver. The aim of the present study was to evaluate the outcome of surgical treatment for CRC with lung metastases. The study retrospectively examined 57 primary CRC patients (28 men, median age of 65 years) with synchronous lung metastases who underwent surgery between 2003 and 2012. Data such as clinicopathological parameters, metastasized organs, and the details of surgery, recurrence and survival periods were extracted and analyzed. Curative resection was performed in 10 patients ('curative group'). Primary tumors were resected without metastasectomy in 37 patients ('non-curative group'), whereas 10 underwent stoma surgery ('stoma group'). All the metastasized lesions were confined to the lung and liver in the curative group. By contrast, 43% of the non-curative/stoma groups had metastases in organs other than the lung and liver. Multivariate analyses indicated the absence of extrahepatic metastases as the only predictor of curative resection in CRC patients with lung metastases. The 3-year overall survival rates for the curative, non-curative and stoma groups were estimated as 74, 20 and 17%, respectively (P=0.0007). In conclusion, curative resection was possible in CRC patients with lung metastases if other disseminated lesions were limited to the liver and this treatment resulted in a longer survival time. Furthermore, palliative resection may contribute to a better prognosis compared to stoma surgery alone in selected cases.

Entities:  

Keywords:  colorectal cancer; curative resection; lung metastasis

Year:  2015        PMID: 26623047      PMCID: PMC4534878          DOI: 10.3892/mco.2015.599

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

1.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

Review 2.  Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer.

Authors:  Roberto Cirocchi; Stefano Trastulli; Iosief Abraha; Nereo Vettoretto; Carlo Boselli; Alessandro Montedori; Amilcare Parisi; Giuseppe Noya; Cameron Platell
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 3.  Metastasectomy for stage IV colorectal cancer.

Authors:  Najjia Mahmoud; Kelli Bullard Dunn
Journal:  Dis Colon Rectum       Date:  2010-07       Impact factor: 4.585

4.  Surgical management of pulmonary metastases from colorectal cancer in 153 patients.

Authors:  Süleyman Yedibela; Peter Klein; Karsta Feuchter; Martin Hoffmann; Thomas Meyer; Thomas Papadopoulos; Jonas Göhl; Werner Hohenberger
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

5.  Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases.

Authors:  S Benoist; K Pautrat; E Mitry; P Rougier; C Penna; B Nordlinger
Journal:  Br J Surg       Date:  2005-09       Impact factor: 6.939

6.  Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone.

Authors:  A P Stillwell; P G Buettner; Y H Ho
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

7.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

8.  Long-term results and prognostic factors after resection of hepatic and pulmonary metastases of colorectal cancer.

Authors:  Silke Schüle; Yves Dittmar; Thomas Knösel; Peter Krieg; Roland Albrecht; Utz Settmacher; Annelore Altendorf-Hofmann
Journal:  Int J Colorectal Dis       Date:  2012-08-11       Impact factor: 2.571

9.  Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases.

Authors:  George Miller; Peter Biernacki; Nancy E Kemeny; Mithat Gonen; Robert Downey; William R Jarnagin; Michael D'Angelica; Yuman Fong; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2007-06-27       Impact factor: 6.113

10.  Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer.

Authors:  K Watanabe; K Nagai; A Kobayashi; M Sugito; N Saito
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.